A new metasurface spectral AI chip enables rapid, accurate diagnosis of meibomian gland dysfunction (MGD) from tissue samples, achieving 96.22% accuracy.
Key Details
- 1Researchers from Peking Union Medical College Hospital and Tsinghua University developed a compact optical AI chip for MGD diagnosis.
- 2The AI chip integrates a spectral convolutional neural network (SCNN) directly onto a CMOS imaging sensor.
- 3Pathological tissue sections from MGD patients and controls were rapidly analyzed, producing spectral feature maps in tens of milliseconds.
- 4The chip identifies MGD with 96.22% accuracy, outperforming conventional RGB image analysis (84%) and matching hyperspectral imaging.
- 5Distinct spectral signatures corresponded with disease severity and biochemical changes in gland tissue.
- 6The device is CMOS-fabricated, enabling potential clinical integration for real-time, objective ocular assessment.
Why It Matters
This innovation demonstrates the power of combining metasurface optics and AI for rapid, objective tissue diagnostics—reducing reliance on subjective clinical assessment and paving the way for real-time, in-sensor medical AI applications.
Source
EurekAlert
Related News
•EurekAlert
AI Accelerates Radiopharmaceuticals, Boosts Personalized Dosimetry in Cancer
Machine learning is driving advancements in radiopharmaceutical drug discovery and optimizing patient-specific dosimetry for precision cancer therapy.
•EurekAlert
Physicians Overly Trust Erroneous AI, Ignore Contradictory Evidence
Physicians tend to trust incorrect AI advice, even when evidence contradicts it, suggesting risks in clinical decision-making with AI tools.
•EurekAlert
Concerns Raised Over Unverified Datasets in AI Health Prediction Models
A new study finds widely used AI health prediction models are built on datasets with unverifiable origins, raising safety and validity concerns.